The potential for nicotinic ligands with affinity for the Î±4Î²2 or Î±7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while preclinical activity in relevant in vivo models has been demonstrated for many more. For several therapeutic programs, we sought nicotinic ligands with various combinations of affinity and function across both subtypes, with an emphasis on dual Î±4Î²2-Î±7 ligands, to explore the possibility of synergistic effects. We report here the structure-activity relationships (SAR) for a novel series of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes and characterize many of the analogues for activity at multiple nicotinic subtypes. Â© 2012 American Chemical Society.
Journal of Medicinal Chemistry
Digital Object Identifier (DOI)
Breining, Scott R.; Melvin, Matt; Bhatti, Balwinder S.; Byrd, Gary D.; Kiser, Melanie N.; Hepler, Christopher D.; Hooker, Dawn N.; Zhang, Jenny; Reynolds, Leslie A.; Benson, Lisa R.; Fedorov, Nikolai B.; Sidach, Serguei S.; Mitchener, J. Pike; Lucero, Linda M.; Lukas, Ronald J.; Whiteaker, Paul; and Yohannes, Daniel, "Structure-Activity Studies Of 7-Heteroaryl-3-Azabicyclo[3.3.1]Non-6-Enes: A Novel Class Of Highly Potent Nicotinic Receptor Ligands" (2012). Translational Neuroscience. 276.